• OPEN AN ACCOUNT
Indian Indices
Nifty
26,033.75 47.75
(0.18%)
Sensex
85,747.83 482.51
( 0.57%)
Bank Nifty
59,288.70 -59.55
( -0.10%)
Nifty IT
38,360.25 535.00
( 1.41%)
Global Indices
Nasdaq
47,874.44 -29.46
(-0.06%)
Dow Jones
6,878.17 7.45
(0.11%)
Hang Seng
50,935.81 1,071.13
(2.15%)
Nikkei 225
9,722.32 30.25
(0.31%)
Forex
USD-INR
90.13 0.27
(0.30%)
EUR-INR
105.04 0.70
(0.67%)
GBP-INR
119.76 1.10
(0.93%)
JPY-INR
0.58 0.00
(0.57%)

EQUITY - MARKET SCREENER

Murae Organisor Ltd
Industry :  Trading
BSE Code
ISIN Demat
Book Value()
542724
INE060601031
1.0194564
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
N.A
3.86
55.21
EPS(TTM)
Face Value()
Div & Yield %
0.07
1
0
 

Zydus receives China NMPA approval for Venlafaxine ER Capsules
Nov 11,2025
Zydus Lifesciences has received approval from the National Medical Products Administration (NMPA), China for Venlafaxine Extended-Release (ER) Capsules, 75 mg and 150 mg.

Venlafaxine ER Capsules are indicated for the treatment of Major Depressive Disorder (MDD), Generalised Anxiety Disorder (GAD), Social Anxiety Disorder (SAD), and Panic Disorder (PD). They help restore the balance of serotonin and norepinephrine in the brain to improve mood and reduce anxiety.

Venlafaxine ER Capsules will be produced at Zydus' manufacturing facility at Moraiya, Ahmedabad.

This is the first approval that the Group has received from NMPA in China.